The approach to optimizing stroke care{star, open}{star, open}Editorial assistance for the development of this manuscript was provided by Mary Ellen Shepard, Boehringer Ingelheim Pharmaceuticals, Inc. This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc.

American Journal of Emergency Medicine

Volumn 26, Issue 7, 2008, Pages 808-816

  Panagos, Peter D ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISABILITY; DRUG CHOICE; FIBRINOLYTIC THERAPY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; WALKING DIFFICULTY;

ASPIRIN; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE; TICLOPIDINE;

EID: 50649118568     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2007.11.014     Document Type: Review

References (74)

1. Ukraintseva S., Sloan F., Arbeev K., et al. Increasing rates of dementia at time of declining mortality from stroke. Stroke 37 (2006) 1155-1159
2. Thom T., Haase N., Rosamond W., et al. Heafs rt disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
3. Williams G.R. Incidence and characteristics of total stroke in the United States. BMC Neurol 1 (2001) 2
4. Hardie K., Hankey G.J., Jamrozik K., Broadhurst R.J., and Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 35 (2004) 731-735
5. Taylor T.N., Davis P.H., Torner J.C., et al. Lifetime cost of stroke in the United States. Stroke 27 (1996) 1459-1466
6. Brown D.L., Lisabeth L.D., Roychoudhury C., et al. Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack. Stroke 36 (2005) 1285-1287
7. Kaplan R.C., Tirschwell D.L., Longstreth Jr. W.T., et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 65 (2005) 835-842
8. Kern R., Steinke W., Daffertshofer M., et al. Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology 65 (2005) 859-864
9. Sacco R.L., Wolf P.A., Kannel W.B., et al. Survival and recurrence following stroke. The Framingham Study. Stroke 13 (1982) 290-295
10. Vickrey B.G., Rector T.S., Wickstrom S.L., et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33 (2002) 901-906
11. Petty G.W., Brown R.D., Whisnant J.P., et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50 (1998) 208-216
12. Johnston S.C., Gress D.R., Browner W.S., et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 (2000) 2901-2906
13. Kleindorfer D., Panagos P., Pancioli A., et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 36 (2005) 720-723
14. Fleck J.D., and Biller J. Choices in medical management for prevention of acute ischemic stroke. Curr Neurol Neurosci Rep. (2001) 33-38
15. Johnston S.C., Sidney S., Bernstein A.L., et al. A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. Neurology 60 (2003) 280-285
16. Wolf P.A., Clagett G.P., Easton J.D., et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30 (1999) 1991-1994
17. Rothwell P.M., Buchan A., and Johnston S.C. Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurol 5 (2006) 323-331
18. Rothwell P.M., and Warlow C.P. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 64 (2005) 817-820
19. Alberts M.J., Hademenos G., Latchaw R.E., et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 283 (2000) 3102-3109
20. Russman A.N., and Katzan I.L. Acute stroke treatment in the community: improving our performance and expanding our options. Semin Neurol 25 (2005) 337-344
21. Adams Jr. H.P., del Zoppo G., Alberts M.J., et al. Guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/America Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke 38 (2007) 1655-1711
22. Greenlund K.J., Neff L.J., Zheng Z.J., et al. Low public recognition of major stroke symptoms. Am J Prev Med 25 (2003) 315-319
23. Billings-Gagliardi S., and Mazor K.M. Development and validation of the stroke action test. Stroke 36 (2005) 1035-1039
24. Harbison J., Hossain O., Jenkinson D., et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the Face Arm Speech Test. Stroke 34 1 (2003) 71-76
25. Evenson K.R., Schroeder E.B., Legare T.B., et al. A comparison of emergency medical services times for stroke and myocardial infarction. Prehosp Emerg Care 5 (2001) 335-339
26. Barber P., Zhang J., Demchuk A., et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
27. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
28. Coull B.M., Williams L.S., Goldstein L.B., et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Neurology 59 (2002) 13-22
29. Chen Z.M., Sandercock P., Pan H.C., et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31 (2000) 1240-1249
30. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
31. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
32. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
33. American Diabetes Association. ADA clinical practice recommendations. Diabetes Care 27 (2004) S1-S143
34. Hillen T., Coshall C., Tilling K., et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 34 (2003) 1457-1463
35. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 241 (1979) 2035-2038
36. Burchfiel C.M., Curb J.D., Rodriguez B.L., et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 25 (1994) 951-957
37. Expert Panel on Detection, Evaluation and Treament of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
38. Anderson J.W., and Konz E.C. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 9 Suppl 4 (2001) 326S-334S
39. Gorelick P.B., Rodin M.B., Langenberg P., et al. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. Neurology 39 (1989) 339-343
40. Lightwood J.M., and Glantz S.A. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 96 (1997) 1089-1096
41. Reeves M.J., Arora S., Broderick J.P., Frankel M., et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 36 (2005) 1232-1240
42. Zaher C., Schloss S., George D., et al. Characterization of ischemic events and use of prescription antiplatelet and anticoagulant agents after stroke or transient ischemic attack. J Stroke Cerebrovasc Dis 14 (2005) 145-151
43. Hillen T., Dundas R., Lawrence E., et al. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke 31 (2000) 469-475
44. Mouradian M.S., Majumdar S.R., Senthilselvan A., et al. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack?. Stroke 33 (2002) 1656-1659
45. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325 (1991) 1261-1266
46. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338 (1991) 1345-1349
47. CAST (Chinese Acute Stroke Trial) Collaborative Group:. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349 (1997) 1641-1649
48. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349 (1997) 1569-1581
49. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
50. Farrell B., Godwin J., Richards S., et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
51. Alberts M.J., Bergman D.L., Molner E., et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
52. Berrouschot J., Schwetlick B., von Twickel G., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113 (2006) 31-35
53. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
54. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
55. Grundmann K., Jaschonek K., Kleine B., et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
56. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
57. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
58. Sztriha LK, Sas K, Vecsei L: Aspirin resistance in stroke: 2004. J Neurol Sci 2005;229-230:163-169.
59. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
60. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
61. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
62. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
63. Fisher M. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist. Arch Neurol 63 (2006) 20-24
64. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
65. Bhatt D.L., and Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263-268
66. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
67. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92 (2004) 311-316
68. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
69. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
70. Sacco R.L., Sivenius J., and Diener H.C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 62 (2005) 403-408
71. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367 (2006) 1665-1673
72. Diener H.C., Sacco R., and Yusuf S. Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Stroke s Trial (PRoFESS). Cerebrovasc Dis 23 (2007) 368-380
73. Serebruany V., Malinin A., Ziai W., et al. Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. Cerebrovasc Dis 21 (2006) 98-105
74. Coull A.J., Lovett J.K., and Rothwell P.M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328 (2004) 326